FDA Should CAP Its Superiority Trial Requirement For Antibiotics, Journal Says
Executive Summary
FDA should refrain from extending its moratorium on non-inferiority trials to antibiotics for the treatment of community-acquired pneumonia, an editorial in The Lancet Infectious Diseases advocates
You may also be interested in...
FDA Still Needs Convincing On Use Of Non-Inferiority Trials For CAP – Temple
Industry has provided little data supporting the use of non-inferiority trials as the basis for approval for community-acquired pneumonia, FDA Office of Medical Policy Director Bob Temple said at a recent workshop on clinical trial design for CAP
NDAs Should Include More Cross-Study Analysis, FDA Says In Draft Guidance
FDA is clarifying that it expects sponsors to provide analysis of efficacy data rather than simply a summary of clinical data as part of the integrated summary of effectiveness in new drug applications
New Look At Ezetimibe Fails To Confirm Vytorin Cancer Signal
Interim data from SHARP and IMPROVE-IT trials fail to show evidence of impact on cancer rates.